Seniz INANCDidem KELEŞ BARTIKGörkem ESKİİZMİRYasemin BAŞPINARGülgün OKTAY2024-07-242024-07-2420192149-7109http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/26615Objective: To assess the effects of Metformin, Dichloroacetate(DCA) and their combination on cell viability in oral squamouscell carcinoma, UPCI-SCC-131 cell line.Methods: UPCI-SCC-131 cells were plated in 96 E-plate (1x104cells/well) and were treated with Metformin (1-16mM) and/orDCA (15-120mM) for 24-48-72h. xCELLigence SP system was usedto monitor real time cell viability. In addition, drug combination index was analyzed with CompuSyn software according toChou-Talalay method.Results: Half-maximal inhibitory concentrations (IC50) of Metformin and DCA were found to be 3mM and 23mM, respectively,for 72 hours. CI values (0.76-0.80) in all combination groups below 1 indicated that Metformin/DCA combination had a moderate synergistic effect on cell viability in UPCI-SCC-131 cells.Discussion: Metformin/DCA combination synergistically decreased the cell viability of UPCI-SCC-131 cells. Therefore, a combined application of Metformin and DCA may be considered asa candidate therapy for the “drug repositioning” of the treatment of oral cavity cancer.engOlgu Sunumu10.32448/entupdates.569464